Peter E J, Steenberg M L, Lokhandwala M F, Jandhyala B S, Eikenburg D C
Drugs. 1985;29 Suppl 2:198-204. doi: 10.2165/00003495-198500292-00035.
The effects of various concentrations (0.01 to 10 mumol/L) of felodipine and verapamil on the peripheral sympathetic function were studied in perfused rat kidney preparations in vitro. Neither of these agents inhibited stimulus-induced 3H-noradrenaline (norepinephrine) release (at 0.5 and 2.0 Hz). Higher concentrations of felodipine (10 mumol/L) and verapamil (1 and 10 mumol/L) significantly potentiated the transmitter release at both frequencies of stimulation. Unlike phentolamine, felodipine 10 mumol/L enhanced the ability of exogenous noradrenaline to inhibit 3H-noradrenaline-release, indicating that this vasodilator did not antagonise prejunctional alpha 2-receptors. The effects of verapamil 1 mumol/L were similar to that of felodipine in this respect; however, verapamil in higher concentrations (10 mumol/L) produced slight but significant attenuation of exogenous noradrenaline-induced inhibition of the transmitter release. Both felodipine and verapamil produced concentration-dependent inhibition of the vasoconstrictor responses to exogenous noradrenaline. It is concluded from these studies that the effects of these agents on the transmitter release may not have any clinical significance, but their ability to attenuate vascular effects of noradrenaline could contribute to their antihypertensive properties.
在体外灌注大鼠肾脏制备物中研究了不同浓度(0.01至10μmol/L)的非洛地平和维拉帕米对外周交感神经功能的影响。这两种药物均未抑制刺激诱导的3H-去甲肾上腺素(去甲肾上腺素)释放(频率为0.5和2.0Hz时)。更高浓度的非洛地平(10μmol/L)和维拉帕米(1和10μmol/L)在两种刺激频率下均显著增强了递质释放。与酚妥拉明不同,10μmol/L的非洛地平增强了外源性去甲肾上腺素抑制3H-去甲肾上腺素释放的能力,表明这种血管扩张剂并未拮抗突触前α2受体。在这方面,1μmol/L维拉帕米的作用与非洛地平相似;然而,更高浓度(10μmol/L)的维拉帕米对外源性去甲肾上腺素诱导的递质释放抑制产生了轻微但显著的减弱。非洛地平和维拉帕米均对外源性去甲肾上腺素引起的血管收缩反应产生浓度依赖性抑制。从这些研究得出结论,这些药物对递质释放的影响可能没有任何临床意义,但它们减弱去甲肾上腺素血管效应的能力可能有助于其降压特性。